tirzepatide molecule CAS-no-2023788-19-2 Tirzepatide molecule, conceptual illustration -
Description
others lose lessindividual variation is substantial
Excess body weight and obesity increases the risk of chronic conditions
Clinical trials show participants lost an average of 15 pounds per month during the first weeks of treatment, with sustained results over one year
Patients concerned about skin laxity during or after GLP-1 treatment should discuss this with their aesthetic provider
2021;384:e42
